The final article in the current series on the major psychiatric drug groups, produced in association with the College of Mental Health Pharmacy. In this article, the authors discuss the use of cognitive enhancers in Alzheimer's disease (AD) and other dementias and provide an overview of new treatments in development.
No takes yet. Share an insight, caveat, or question.
Bishara et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: